Web services robustness testing

Web services are a new paradigm for building software applications that has many advantages over the previous paradigms; however, Web Services are still not widely used because Service Requesters do not trust services that were built by others. Testing can assuage this problem because it can be used to assess the quality attributes of Web Services. This thesis proposes a framework and presents a proof of concept tool that can be used to test the robustness and other related attributes of a Web Service. The tool can be easily enhanced to assess other quality attributes. The framework is based on analyzing Web Services Description Language (WSDL) documents of Web Services to find what faults could affect the robustness quality attributes. After that using these faults to build test case generation rules to assess the robustness quality attribute of Web Services. This framework will give a better understanding of the faults that may affect the robustness quality attribute of Web Services, how these faults are related to the interface or the contract of a Web Service under test, and what testing techniques can be used to detect such faults. The approach used in this thesis for building test cases for Web Services was used with many examples in order to demonstrate its effectiveness; these examples have shown that the approach and the proof of concept tool are able to assess the robustness of Web Services implementation and Web Services platforms. Four hundred and two test clients were automatically built by the tool, based on the test cases rules, to assess the robustness of these Web Services examples. These test clients detected eleven robustness failures in the Web Services implementations and nine robustness failures in the Web Services platforms. Also the approach was able to help in comparing the robustness of two different Web Services platforms, namely Axis and GLUE. After deploying the same Web Services in both of these platforms; Axis showed less robustness and security failures than GLUE

Software Defined Radio Implementation of Carrier and Timing Synchronization for Distributed Arrays

The communication range of wireless networks can be greatly improved by using distributed beamforming from a set of independent radio nodes. One of the key challenges in establishing a beamformed communication link from separate radios is achieving carrier frequency and sample timing synchronization. This paper describes an implementation that addresses both carrier frequency and sample timing synchronization simultaneously using RF signaling between designated master and slave nodes. By using a pilot signal transmitted by the master node, each slave estimates and tracks the frequency and timing offset and digitally compensates for them. A real-time implementation of the proposed system was developed in GNU Radio and tested with Ettus USRP N210 software defined radios. The measurements show that the distributed array can reach a residual frequency error of 5 Hz and a residual timing offset of 1/16 the sample duration for 70 percent of the time. This performance enables distributed beamforming for range extension applications.Comment: Submitted to 2019 IEEE Aerospace Conferenc

Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [177Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience

Well-received strong efficacy of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) does not prevent patients from either early or eventual disease progression under this treatment. In this study, we investigated co-medication with enzalutamide as a potential re-sensitizer for PSMA-RLT in patients with imminent treatment failure on standard 177Lu-based PSMA-RLT. Ten mCRPC patients who exhibited an insufficient response to conventional [177Lu]Lu PSMA-617 RLT received oral medication of enzalutamide 160 mg/d as an adjunct to continued PSMA RLT. Prostate-specific antigen (PSA) and standard toxicity screening lab work-up were performed to assess the treatment efficacy and safety in these individuals. The mean PSA increase under PSMA-RLT before starting the re-sensitizing procedure was 22.4 ± 26.5%. After the introduction of enzalutamide medication, all patients experienced a PSA decrease, –43.4 ± 20.0% and –48.2 ± 39.0%, after one and two cycles of enzalutamide-augmented PSMA-RLT, respectively. A total of 70% of patients (7/10) experienced partial remission, with a median best PSA response of –62%. Moreover, 5/6 enzalutamide-naïve patients and 2/4 patients who had previously failed enzalutamide exhibited a partial remission. There was no relevant enzalutamide-induced toxicity observed in this small cohort. This pilot experience suggests the synergistic potential of adding enzalutamide to PSMA-RLT derived from the intra-individual comparison of 177Lu-based PSMA-RLT ± enzalutamide

Activity of highly dispersed Co/SBA-15 catalysts (low content) in carbon black oxidation

Peer reviewedPublisher PD